Dr. Galsky on Progression on Immunotherapy in Bladder Cancer

(59)

Dr. Galsky Discusses Neoadjuvant Immunotherapy in Bladder Cancer

(1:36)

Dr. Galsky Discusses Combination Immunotherapy in Bladder Cancer

(1:58)

Dr. Galsky on the Geographic Accessibility of Prostate Cancer Clinical Trials

(2:10)

Dr. Galsky on Targeted Therapies in Bladder Cancer

(2:3)

Matthew Galsky Gives an Overview of Bladder Cancer

(1:35)

മാരക രോഗങ്ങൾക്ക് വിട - ന്യൂട്രീഷൻ ചികിത്സയിലൂടെ അത്ഭുത രോഗശാന്തി EXCLUSIVE INTERVIEW DR.A.SREEKUMAR

(31:55)

കാൻസർ? പേടിക്കാതെ ജീവിക്കാം || cancer live without fear || EP 117

(59:12)

Cancer Treatment in CKD Patients - Prof. Dr. Sabine Karam, Prof. Dr. Jolanta Małyszko

(57:30)

Bladder Panel Reacts to EV-302 Data Presented at ESMO 2023

(6:31)

Port Moody Health DCA (Dichloroacetate) Treatment

(2:30)

อย่านิ่งนอนใจ! อาการเตือนโรคระบบทางเดินปัสสาวะ | บำรุงราษฎร์

(5:19)

Deciphering Immuno-Oncology: Targeting Cellular Mechanisms of the Tumor Immune Response

(1:2:29)

30% of stage 4 bladder cancer patients can now go on to live beyond five years: Dr. Shyam Aggarwal

(4:31)

How is Advanced Bladder Cancer Treated?

(6:46)

Nivo+Gem/Cis Is Durable, Improves Survival in Patients With Lymph Node–Only mUC

(7:52)

Dr. Galsky on the Role of Ipilimumab in Bladder Cancer

(1:9)

Dr. Matthew Galsky - ASCO 2021

(4:22)

Dr. Galsky Discusses the Rationale for the IMvigor130 Study in Bladder Cancer

(2:19)

Dr. Galsky on Neoadjuvant Immune Checkpoint Blockade in Bladder Cancer

(1:35)

Dr. Galsky on Ipilimumab in Bladder Cancer

(1:7)

Matthew Galsky, MD, shares a message for patients regarding clinical progress in bladder cancer

(1:8)

Dr. Matthew Galsky on abiraterone

(3:17)

ASCO GU 2020: Dr. Galsky Provides Insight on Potentially Practice-Changing Studies in Bladder Cancer

(7:40)

Matthew Galsky, MD, discusses how to identify patients that will likely be good responders for I-O

(2:14)

ESMO Dr. Galsky

(2:52)

Dr. Galsky on Resistance to Checkpoint Blockade in Metastatic Bladder Cancer

(59)

Galsky: Adjuvant Chemo vs. Observation in Bladder Cancer

(2:34)

Dr. Galsky on Maintenance Pembrolizumab in Urothelial Cancer

(2:21)

Dr. Galsky on Sequencing Questions in Urothelial Cancer

(1:20)